Catabolic enzymes in chondrocytes and cartilage matrix gene regulation

Catabolic enzymes in chondrocytes and cartilage matrix gene regulation refers to the complex biochemical network responsible for the degradation of the extracellular matrix (ECM) in articular cartilage, primarily driven by matrix metalloproteinases (MMPs) and a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) [1]. In healthy cartilage, a balance exists between the synthesis of matrix components like type II collagen and aggrecan and their controlled turnover; however, in diseases like osteoarthritis, pro-inflammatory cytokines such as IL-1β and TNF-α shift this balance toward catabolism [2, 3]. These cytokines activate signaling pathways, such as NF-κB and MAPK, that upregulate catabolic enzymes while simultaneously downregulating anabolic transcription factors like SOX9 [3]. MMP-13 is specifically recognized as the most potent collagenase in this process, while ADAMTS-4 and ADAMTS-5 are the primary drivers of aggrecan loss [2]. Therapeutic interventions have historically focused on broad-spectrum MMP inhibitors, which failed in clinical trials due to musculoskeletal toxicity, leading to a current focus on highly selective ADAMTS inhibitors and cytokine modulators [1, 4]. Understanding this regulatory network is crucial for developing disease-modifying osteoarthritis drugs (DMOADs) that can halt or reverse joint degeneration [5].

Other names

Cartilage catabolic pathwayChondrocyte-mediated matrix degradationOsteoarthritis catabolic signalingMMP and ADAMTS regulation in cartilage

Inhibition of matrix-degrading proteases (MMPs and ADAMTS) and modulation of pro-inflammatory signaling (IL-1, TNF) to prevent cartilage matrix breakdown and promote anabolic gene expression [1, 2, 3].